MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.145
-0.005
-0.43%
Opening 10:07 06/08 EDT
OPEN
1.140
PREV CLOSE
1.150
HIGH
1.150
LOW
1.140
VOLUME
30.50K
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
1.090
MARKET CAP
70.90M
P/E (TTM)
-0.6217
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (0601-0605)?
Weekly Report · 3h ago
Weekly Report: what happened at PLRX last week (0525-0529)?
Weekly Report · 06/01 10:18
Weekly Report: what happened at PLRX last week (0518-0522)?
Weekly Report · 05/25 10:21
Pliant Therapeutics to present PLN-101095 trial data at ASCO meeting
PUBT · 05/21 21:29
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Barchart · 05/21 16:29
Weekly Report: what happened at PLRX last week (0511-0515)?
Weekly Report · 05/18 10:21
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 05/13 04:55
Analyst Reiterates Hold on Pliant Therapeutics, Keeps 12-Month Price Target Unchanged at $3 Amid Early-Stage Risk-Reward Balance
TipRanks · 05/12 12:25
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.